otaplimastat

Neuroprotectant from purified coelomic fluid of live earth worm (Eisenia andrei)

Also Known As:

N-(3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl)-N-(4-(3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylaminogbutyl)acetamide); SP-8203

Networked: 7 relevant articles (3 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Acetamides: 21
    - otaplimastat: 7
- Carboxylic Acids: 973
  - Acyclic Acids
    - Acetates: 4994
      - Acetamides: 21
        otaplimastat: 7
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - Quinazolinones: 124
        otaplimastat: 7

Experts

1.	Ju, Chung: 2 articles (01/2022 - 01/2020)
2.	Kim, Won-Ki: 2 articles (01/2022 - 01/2020)
3.	Lee, Ki Sung: 2 articles (01/2022 - 11/2011)
4.	Ryu, Jei-Man: 2 articles (01/2022 - 01/2020)
5.	Cho, Il Hwan: 2 articles (11/2011 - 03/2011)
6.	Kim, Hye-Sun: 2 articles (11/2011 - 03/2011)
7.	Lee, Chul Kyu: 2 articles (11/2011 - 03/2011)
8.	Noh, Su-Jin: 2 articles (11/2011 - 03/2011)
9.	Suh, Yoo-Hun: 2 articles (11/2011 - 03/2011)
10.	Chung, Jee-In: 1 article (01/2022)

Related Diseases

1.	Ischemic Stroke 03/01/2011 - "Therefore, SP-8203 may be more effective for multiple-target mechanisms of ischemic stroke." 01/01/2020 - "Safety and Efficacy of Otaplimastat in Patients with Acute Ischemic Stroke Requiring tPA (SAFE-TPA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study."
2.	Edema (Dropsy) 01/26/2022 - "Otaplimastat reduced cerebral infarct size and edema and improved neurobehavioral deficits. " 01/01/2020 - "Otaplimastat is a neuroprotectant that inhibits matrix metalloprotease pathway, and reduces edema and intracerebral hemorrhage induced by recombinant tissue plasminogen activator (rtPA) in animal stroke models. "
3.	Cerebral Infarction 01/26/2022 - "Otaplimastat reduced cerebral infarct size and edema and improved neurobehavioral deficits. " 07/01/2010 - "The pharmacokinetics of SP-8203, a potential protective agent for the treatment of cerebral infarction, were evaluated after its intravenous (10, 20 and 30 mg/kg) and oral (10, 20, 30 and 100 mg/kg) administration in rats. "
4.	Stroke (Strokes) 01/26/2022 - "This paper shows that otaplimastat under clinical trials is a new drug which can inhibit stroke on its own and extend the therapeutic time window of rtPA, especially when administered in combination with rtPA." 01/01/2020 - "Otaplimastat is a neuroprotectant that inhibits matrix metalloprotease pathway, and reduces edema and intracerebral hemorrhage induced by recombinant tissue plasminogen activator (rtPA) in animal stroke models. "
5.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/26/2022 - "In the present study, we investigated whether the neuroprotant otaplimastat reduced delayed rtPA treatment-evoked neurotoxicity in male Sprague Dawley rats subjected to embolic middle cerebral artery occlusion (eMCAO). " 11/01/2011 - "The systemic administration of SP-8203 markedly reduced neuronal death following middle cerebral artery occlusion in rats. "

Related Drugs and Biologics

1.	Neuroprotective Agents
2.	Metalloproteases (Metalloproteinases)
3.	Matrix Metalloproteinases (MMPs)
4.	Protective Agents
5.	Tissue Inhibitor of Metalloproteinases
6.	Dizocilpine Maleate (Dizocilpine)
7.	N-Methyl-D-Aspartate Receptors (NMDA Receptors)
8.	Verapamil (Calan)
9.	Quinazolines
10.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Therapeutics